Class Action Lawsuit Filed Against Nektar Therapeutics Over Alleged Misleading Statements
A class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) by Bronstein, Gewirtz & Grossman LLC, alleging that the company made false and misleading statements regarding its REZOLVE-AA trial. The lawsuit claims that the trial's enrollment did not follow proper protocols, potentially affecting its results and overstating the trial's integrity. Investors who purchased Nektar securities between February 26, 2025, and December 25, 2025, are encouraged to join the case.
Tickers: $NKTR
Topics: class action legal action Nektar Therapeutics REZOLVE-AA trial securities fraud